Itonis Inc (ITNS)

$0.00 0.00 (N/A)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 10,700
Avg Vol 612,842
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 50%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Itonis, Inc., a development stage company, focuses on producing and marketing over the counter and prescription homeopathic preparations to treat common ailments and chronic diseases. The company intends to sells its over-the-counter to alleviate mild to moderate nausea. It has placed a manufacturing order for the first batch of its Emesyl product line. The company was formerly known as Kenshou, Inc. and changed its name to Itonis, Inc. in December 2005. Itonis, Inc. was founded in 2005 and is h...

Industry: Medical Distribution
Sector: Healthcare
Phone: 949-200-8887
Address:
22951 Mill Creek Drive, Suite A-1, Laguna Hills, United States
trprofit
trprofit Mar. 13 at 7:09 PM
$ITNS AR is out and contains the same In 2021, the Company agreed with CVS Pharmacy to participate in their Test & Learn Program for our Emesyl® product. We had expected to gather feedback with performance metrics via an online dashboard to develop action plans for sales success. CVS seemed to like the uniqueness of Emesyl® with it being “Homeopathic” and the “only fast acting nasal spray” on the market. Meanwhile, the Company’s Itonis Holdings, Inc. subsidiary owns and manages the entirety of the Emesyl® nausea relief product line by full assignment of all the patent rights in Emesyl® nausea relief from the inventor. The Company has organized said Itonis Pharmaceuticals division and its Emesyl® and Emesyl® Product line within its wholly-owned subsidiary, Itonis Holdings, Inc. On or about March 28, 2023, the Company transferred its Emesyl Plus product to Smart Cannabis Inc. in exchange for 147,000,000 shares of Smart Cannabis, Inc’s common stock.
0 · Reply
trprofit
trprofit Mar. 11 at 11:37 AM
$ITNS Still breathing, eh? Note the 3333 share trades
0 · Reply
skagnetti13
skagnetti13 Jan. 24 at 12:28 AM
$ITNS How many others are trapped in here with me??🤣
0 · Reply
NevD
NevD Jan. 8 at 4:16 AM
$ITNS
0 · Reply
NevD
NevD Jan. 2 at 4:00 PM
$ITNS this need 0.0006 or better.
0 · Reply
trprofit
trprofit Nov. 25 at 7:20 PM
$ITNS QUARTERLY 10/27/24 INFO THE SAME In 2021, the Company agreed with CVS Pharmacy to participate in their Test & Learn Program for our Emesyl® product. We fulfilled various purchase orders from CVS which involved shipping Emesyl® products to two CVS distribution centers in Texas. We had expected to gather feedback with performance metrics via an online dashboard to develop action plans for sales success. Meanwhile, the Company’s Itonis Holdings, Inc. subsidiary owns and manages the entirety of the Emesyl® nausea relief product line. The Company has organized said Itonis Pharmaceuticals division and its Emesyl® and Emesyl® Product line within its wholly-owned subsidiary, Itonis Holdings, Inc. On or about March 28, 2023, the Company transferred its Emesyl Plus product to Smart Cannabis Inc. in exchange for 147,000,000 shares of Smart Cannabis, Inc’s common stock
1 · Reply
NevD
NevD Oct. 8 at 7:54 PM
$ITNS I bought this in the Pennie’s… 🥺
1 · Reply
NevD
NevD Aug. 22 at 9:34 PM
$ITNS
0 · Reply
trprofit
trprofit Jul. 31 at 11:49 PM
$ITNS Quarterly was out July 20. Same info as last one (CVS and Smart Cannabis Inc.) Maybe something will actually happen!!!!!!
2 · Reply
trprofit
trprofit May. 31 at 1:51 PM
$ITNS Back to pink current. Why bother, unless......?
0 · Reply
Latest News on ITNS
No data available.
trprofit
trprofit Mar. 13 at 7:09 PM
$ITNS AR is out and contains the same In 2021, the Company agreed with CVS Pharmacy to participate in their Test & Learn Program for our Emesyl® product. We had expected to gather feedback with performance metrics via an online dashboard to develop action plans for sales success. CVS seemed to like the uniqueness of Emesyl® with it being “Homeopathic” and the “only fast acting nasal spray” on the market. Meanwhile, the Company’s Itonis Holdings, Inc. subsidiary owns and manages the entirety of the Emesyl® nausea relief product line by full assignment of all the patent rights in Emesyl® nausea relief from the inventor. The Company has organized said Itonis Pharmaceuticals division and its Emesyl® and Emesyl® Product line within its wholly-owned subsidiary, Itonis Holdings, Inc. On or about March 28, 2023, the Company transferred its Emesyl Plus product to Smart Cannabis Inc. in exchange for 147,000,000 shares of Smart Cannabis, Inc’s common stock.
0 · Reply
trprofit
trprofit Mar. 11 at 11:37 AM
$ITNS Still breathing, eh? Note the 3333 share trades
0 · Reply
skagnetti13
skagnetti13 Jan. 24 at 12:28 AM
$ITNS How many others are trapped in here with me??🤣
0 · Reply
NevD
NevD Jan. 8 at 4:16 AM
$ITNS
0 · Reply
NevD
NevD Jan. 2 at 4:00 PM
$ITNS this need 0.0006 or better.
0 · Reply
trprofit
trprofit Nov. 25 at 7:20 PM
$ITNS QUARTERLY 10/27/24 INFO THE SAME In 2021, the Company agreed with CVS Pharmacy to participate in their Test & Learn Program for our Emesyl® product. We fulfilled various purchase orders from CVS which involved shipping Emesyl® products to two CVS distribution centers in Texas. We had expected to gather feedback with performance metrics via an online dashboard to develop action plans for sales success. Meanwhile, the Company’s Itonis Holdings, Inc. subsidiary owns and manages the entirety of the Emesyl® nausea relief product line. The Company has organized said Itonis Pharmaceuticals division and its Emesyl® and Emesyl® Product line within its wholly-owned subsidiary, Itonis Holdings, Inc. On or about March 28, 2023, the Company transferred its Emesyl Plus product to Smart Cannabis Inc. in exchange for 147,000,000 shares of Smart Cannabis, Inc’s common stock
1 · Reply
NevD
NevD Oct. 8 at 7:54 PM
$ITNS I bought this in the Pennie’s… 🥺
1 · Reply
NevD
NevD Aug. 22 at 9:34 PM
$ITNS
0 · Reply
trprofit
trprofit Jul. 31 at 11:49 PM
$ITNS Quarterly was out July 20. Same info as last one (CVS and Smart Cannabis Inc.) Maybe something will actually happen!!!!!!
2 · Reply
trprofit
trprofit May. 31 at 1:51 PM
$ITNS Back to pink current. Why bother, unless......?
0 · Reply
skagnetti13
skagnetti13 May. 30 at 2:21 AM
$ITNS What the hell is going on here?? Same pattern almost every single day. Some days close at .004 and some at .005. No news, no fillings, weird company.
0 · Reply
trprofit
trprofit May. 2 at 12:03 PM
$ITNS So....is something happening or not?
2 · Reply
trprofit
trprofit Apr. 16 at 11:12 AM
$ITNS Quarterly also referenced this: On or about March 28, 2023, the Company transferred its Emesyl Plus product to Smart Cannabis Inc. in exchange for 147,000,000 shares of Smart Cannabis, Inc’s common stock." Smart Cannabis Corp. (SCNA) .0002
0 · Reply
trprofit
trprofit Apr. 16 at 11:11 AM
$ITNS Quarterly out yesterday. Referenced this: "In 2021, the Company agreed with CVS Pharmacy to participate in their Test & Learn Program for our Emesyl® product. We fulfilled various purchase orders from CVS which involved shipping Emesyl® products to two CVS distribution centers in Texas. We had expected to gather feedback with performance metrics via an online dashboard to develop action plans for sales success. CVS seemed to like the uniqueness of Emesyl® with it being “Homeopathic” and the “only fast acting nasal spray” on the market."
0 · Reply
skagnetti13
skagnetti13 Apr. 8 at 3:28 PM
$ITNS Morning all!! Just hopped in with 2 mil shares.
0 · Reply
IAmMsMoneyMaker
IAmMsMoneyMaker Apr. 8 at 2:20 PM
$ITNS This will go parabolic soon IMO! 🥳🚀🚀🚀🚀🚀🚀🚀🚀🚀 Just Watch…⏳⌛️
0 · Reply
NevD
NevD Apr. 7 at 5:50 PM
$ITNS this baby was consistently in the 0012 to 0018 range a yr ago. It’s going past 0013 very soon. It hit 0013 last week. Buckle up. 🤓😎
0 · Reply
Jrohmfeld
Jrohmfeld Mar. 31 at 6:33 AM
$ITNS what is going on here?? 😏
0 · Reply
NevD
NevD Mar. 29 at 3:46 PM
$ITNS dammit..sold at .0009. Oh well. Good job everyone.
0 · Reply
trprofit
trprofit Mar. 29 at 12:29 AM
$ITNS Maybe the CVS deal???????? 01/16/2024 Annual Report - Itonis' Annual Report, ending November 30, 2023 Describe the issuers’ principal products or services. "In 2021, the Company agreed with CVS Pharmacy to participate in their Test & Learn Program for our Emesyl® product. We fulfilled various purchase orders from CVS which involved shipping Emesyl® products to two CVS distribution centers in Texas. We had expected to gather feedback with performance metrics via an online dashboard to develop action plans for sales success. CVS seemed to like the uniqueness of Emesyl® with it being “Homeopathic” and the “only fast acting nasal spray” on the market. If the success criteria are met, an action plan will be developed by the CVS category manager to expand distribution to more of their stores, which is typically executed in their next CVS planogram cycle. We will see what the Test & Learn Program will tell us"
0 · Reply
trprofit
trprofit Mar. 28 at 6:24 PM
$ITNS NOW PINK CURRENT! Appears to be taking off!
0 · Reply
trprofit
trprofit Jan. 30 at 4:17 PM
$ITNS New Annual Report Is Out
1 · Reply